Literature DB >> 28866044

Investigation of the preventive effect of Sijunzi decoction on mitomycin C-induced immunotoxicity in rats by 1H NMR and MS-based untargeted metabolomic analysis.

Zhibo Guan1, Juan Wu2, Cancan Wang3, Fang Zhang4, Yinan Wang5, Miao Wang6, Min Zhao7, Chunjie Zhao8.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Sijunzi decoction (SJZD) is a well known traditional Chinese prescription used for the treatment of gastrointestinal disorders and immunity enhancement. It has been found to indeed improve life quality of chemotherapy patients and extensive used in clinical conbined with chemotherapeutics for the treatment of cancer. AIM OF THE STUDY: The aim of this study was to investigate the preventive effect of the immunotoxicity of SJZD on mitomycin C (MMC) and the metabolic mechanism of action.
MATERIALS AND METHODS: NMR and MS-based metabolomics approaches were combined for monitoring MMC-induced immunotoxicity and the protective effect of SJZD. Body weight change and mortality, histopathological observations and relative viscera weight determinations of spleen and thymus, sternum micronucleus assay and hematological analysis were used to confirm the immunotoxicity and attenuation effects. An OPLS-DA approach was used to screen potential biomarkers of immunotoxicity and the MetaboAnalyst and KEGG PATHWAY Database were used to investigate the metabolic pathways.
RESULTS: 8 biomarkers in plasma samples, 19 in urine samples and 10 in spleen samples were identified as being primarily involved in amino acid metabolism, carbohydrate metabolism and lipid metabolism. The most critical pathway was alanine, aspartate and glutamate metabolism.
CONCLUSIONS: The variations in biomarkers revealed the preventive effect of the immunotoxicity of SJZD on MMC and significant for speculating the possible metabolic mechanism.
Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  (1)H NMR; 16-deoxyporicoic acid B (PubChem CID: 16736458); Immunotoxicity; MS; Metabolomics; Mitomycin C; Sijunzi decoction; atractylenolide I (PubChem CID: 5321018); atractylenolide II (PubChem CID: 14448070); atractylenolide III (PubChem CID: 155948); gancaonin I (PubChem CID: 480777); ginsenoside Re (PubChem CID: 441921); ginsenoside Rg(2) (PubChem CID: 75412551); liquiritigenin (PubChem CID: 114829); poricoic acid B (PubChem CID: 5471852)

Mesh:

Substances:

Year:  2017        PMID: 28866044     DOI: 10.1016/j.jep.2017.08.021

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  5 in total

1.  Enteral Nutrition Combined with Improved-Sijunzi Decoction Shows Positive Effect in Precachexia Cancer Patients: A Retrospective Analysis.

Authors:  Yueying Li; Yajun Chen; Yaqi Zeng; Jie Dong; Chunlei Li; Yingjie Jia; Yonghua Zhao; Kun Wang
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-22       Impact factor: 2.629

2.  Tissue metabolomics study to reveal the toxicity of a traditional Tibetan medicine 'Renqing Changjue' in rats.

Authors:  Can Xu; Yingfeng Wang; Caidan Rezeng; Lan Zhang; Baosheng Zhao; Xia Wang; Xiuyuan Wu; Zhongfeng Li; Jianxin Chen
Journal:  RSC Adv       Date:  2018-11-08       Impact factor: 4.036

3.  Spectrum-Effect Relationship between UPLC Fingerprints and Antilung Cancer Effect of Si Jun Zi Tang.

Authors:  Xiaowei Zhou; Ying Li; Mingyu Zhang; Junjie Hao; Qiong Gu; Haiyang Liu; Wei Chen; Yafei Shi; Bin Dong; Yuanyuan Zhang; Chunyu Li; Guohui Li
Journal:  Evid Based Complement Alternat Med       Date:  2019-09-22       Impact factor: 2.629

4.  Modified Sijunzi Decoction Inhibits Epithelial-Mesenchymal Transition of Non-Small Cell Lung Cancer by Attenuating AKT/GSK3β Pathway in vitro and in vivo.

Authors:  Niu Shao; Yao Xiao; Jiaxin Zhang; Yuying Zhu; Shenglong Wang; Suzhen Bao
Journal:  Front Pharmacol       Date:  2022-01-17       Impact factor: 5.810

5.  Effect of Single-Dose and Short-Term Administration of Si Jun Zi Tang on the Pharmacokinetics of Gefitinib in Rats.

Authors:  Ying Li; Xiaowei Zhou; Ming Niu; Mingyu Zhang; Qiong Gu; Wei Chen; Bin Dong; Yuanyuan Zhang; Ruisheng Li; Chunyu Li; Guohui Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-26       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.